Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Executive Summary
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
You may also be interested in...
Senate CEO Hearing On Drug Prices Could (Almost) Have Taken Place Five Years Ago
Discussion around the landmark developments in pricing reform established by the Inflation Reduction Act of 2022 were largely absent from the hearing involving Johnson & Johnson’s Joaquin Duato, Merck’s Robert Davis and Bristol Myers Squibb’s Chris Boerner.
Bernie vs. CEOs: Are J&J, Merck, And Bristol On Hot Seat, Or Is Medicare Price Negotiation?
Sen. Bernie Sanders threatening subpoenas to compel the CEOs of J&J and Merck to testify along with Bristol Myers Squibb CEO at upcoming hearing. They say they are being hassled because of their legal challenges to the IRA; Sanders says he wants to focus on Rx prices vs. foreign countries.
Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.